Praxis Precision Medicine Reports Wider Q4 Loss, Analysts Adjust Price Targets
Praxis Precision Medicine reported Q4 losses of $3.50 per share, missing analyst estimates of $3.08 per share. Following the earnings announcement, analysts maintained their ratings while raising price targets across the board.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported its Q4 earnings results on Thursday, February 19, 2026 at 07:30 AM. The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share, representing a miss of 13.64%.
Revenue was down $7.46 million from the same period last year.
Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday. Shares of Praxis Precision Medicine were trading at $328.04 as of February 17. Over the last 52-week period, shares are up 317.71%.
Following the earnings announcement, analysts made changes to their price targets on Praxis Precision Medicine. An analyst maintained Praxis Precision Medicine with an Underperform rating and raised the price target from $95 to $130. An analyst maintained the stock with a Buy and raised the price target from $500 to $700. An analyst maintained Praxis Precision Medicine with an Outperform rating and raised the price target from $275 to $433.
In the previous quarter, the company beat on EPS by $0.11, resulting in a 4.68% increase change in the share price the following day.